Replies to post #63336 on NorthWest Biotherapeutics Inc (NWBO)

[Poor Man -]

I think their plan has been to get value for shareholders by holding on until they get phase 3 done. That would be the time to either sell or partner for the more significant clinical program that is now needed. I think they can limp across the finish line of phase 3 and I am hopeful the second half of this year is much more fun that the first. The key is for the regulatory issue/opportunity to clear up and it is still the real timing wildcard here.

Well stated and I agree with your points. The only difference is the conclusion I draw from your last sentence. There is now a much higher level of uncertainty just based on how the last capital raised played out. Management was basically saying: let's take the relatively small amount of cash now and concede to repricing the long dated warrants to $1 a share, because we're increasingly uncertain about the future timing. Maybe there's where the hope is to limp across the finish line?

In my opinion, the timing and the placing of the finish line has become such a wildcard that management needs to be engaging potential buyers just as a matter of fiduciary responsibility. And then they can make a definitive decision based on offers, the corporate outlook, and what (if any) guidance they receive from the FDA.

If the question about selling NWBO hasn't been raised by the investors in the Toucan Capital fund, I would be surprised - unless they are very, very passive.